The rationale for testing empagliflozin in the full range of people at risk of CKD progression was based on findings from the EMPA-REG OUTCOME trial [15] and other clinical and experimental data, which showed SGLT-2 inhibitors induce glycosuria and lower BP and albuminuria [28–30]. The gene discussed is SLC5A2; the disease is chronic kidney disease.